Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Small Cell Lung Carcinoma 3Thrombocytosis 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Carcinosarcoma 1

Interventions

Specimen Handling 9Paclitaxel 7Magnetic Resonance Spectroscopy 6Carboplatin 6Biopsy 6Nivolumab 5pembrolizumab 3olaparib 3X-Rays 3durvalumab 2ceralasertib 2cediranib 2Taxes 2Immunoglobulin G 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pazopanib 1pamiparib 1liposomal doxorubicin 1cobimetinib 1capivasertib 1cabozantinib 1belinostat 1atezolizumab 1apatinib 1Trabectedin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × pelcitoclax × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡